Kidney Stones
|
In the most severe cases of kidney stones - patients that need surgical
intervention to remove the stones – taking the systemic
enzymes made them significantly less likely to get stones
again. Now what is interesting is that in those studies, the patients took enzymes for only four to five weeks – but they still had less risk of developing new kidney stones a year later!! From what I have been able to find in the literature, I would say that by decreasing inflammation (and decreasing pro-inflammatory cytokines such as IL-6 – which is associated with kidney stone formation) , and pro-Wobenzym is able to inhibit the development of kidney stones decrease the inflammatory. But more than that, the enzymes in Wobenzym have proteolytic properties may decrease formation of the organic (protein) component of the kidney stone. In addition, the enzymes appear to be interacting with bikunin, a glycoprotein that is a member of the inter-alpha-trypsin inhibitor (ITI) family. Like alpha-2-macroglobulin, the ITI family of glycoproteins modulate inflammation. Proper function of bikunin decreases calcium oxylate stone formation. We also note that patients with kidney stones complicated by pyelonephritis have very high levels of SIgA (secretory IgA) an immunoglobulin involved in local immunity of mucus membranes. This increase in the urine level of SIgA in patients with kidneys stones and pyelonephritis can play apart in the development of kidney stones. By normalizing urinary system local immunity, Wobenzym can decreases kidney stone formation. So, there are a number of mechanisms by which Woebnzym-N can decrease kidney stone formation. From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND Read the special section: KIDNEY AND BLADDER CONDITIONS & WOBENZYM® |
What the literature says about Systemic Enzyme Support and:
Coenzyme
metabolic assurance of patients with recurrent nephrolithiasis in
the complex treatment by systemic enzyme therapy.
Borisov O.V. Coenzyme
metabolic assurance of patients with recurrent nephrolithiasis in
the complex treatment by systemic enzyme therapy. Urologia 1998, 3,
pp. 29-35. Odessa Medical University, Department of Urology, Odessa,
Ukraine. [Abstract available in Ukrainian.]
In addition to clinico-immunological
investigation, the metabolic supply of enzymatic systems with
pyridoxal phosphate and thiamin pyrophosphate was studied in 50
patients with recurrent nephrolithiasis complicated by chronic
pyelonephritis. It was established that the value of thiamin
pyrophosphate - effect was reliably increased in patients with
nephrolithiasis, this witnessing the insufficient metabolic supply
with coenzyme form of vitamin B1-cocarboxylase. There was a strong
tendency to the growth of pyridoxal phosphate-effect. The complex
treatment of patients included antiinflammatory, antibacterial
therapy, as well as operative intervention in the upper urinary
tract. 25 patients additionally received polyenzyme preparation
Phlogenzym in the early postoperative period (for 2-3 weeks) and as
out-patients (for 2 weeks more).
The complex treatment of nephrolithic patients
with the use of Phlogenzym produced marked normalizing influence on
the value of pyridoxal phosphate-effect which is indicative of the
reduction of alterations in the urinary tract tissues. The
postoperative period had a favourable course, and the control
check-up carried out 12 months later revealed that the incidence of
lithogeny recurrence was reliably lower than in the control group.
Poster Reference Number 33.
Immunological aspects of systemic enzyme therapy (SET) in the
complex treatment of recurrent nephrolithiasis.
Borisov A.V., Ukhal M.I., Kabak Yu.A., Borisov
S.A. Immunological aspects of systemic enzyme therapy (SET) in the
complex treatment of recurrent nephrolithiasis. 1st National
Congress of the Ukraine on Immunology, Allergology, and
Immunorehabilitation. Odessa State Medical University. [Russian
version]
Treatment of 50 patients suffering from
nephrolithiasis, complicated by a chronic pyelonephritis in the
active stage of inflammation was studied. Clinical status, urinary
concretions, as well as immunological examination (E-RFC, T-helpers,
T-suppressors and their ratio) and humoral immunity parameters
(EAC-RFC , serum immunoglobulins, CIC) were examined. Additionally,
NBT-test, phagocytary activity and index and complement system were
studied.20 patients, treated by an antiinflammatory therapy and
surgery, received also Phlogenzym (2 tbl. 4 times a day for 4
weeks).
After the finishing of a complex therapy patients
were examined again and results were compared to those with and
without Phlogenzym administration.
Patients treated by Phlogenzym showed:
increase in total T-lymphocyte population;
normalization of T-helpers/T-suppressors ratio;
decreased CIC level;
normalization of neutrophil intracellular bactericidal
systems.
Positive immunological changes correlated with a
favourable dynamics of various clinical parameters:
non-complicated healing of postsurgical wound;
no chronic pyelonephritis deterioration;
faster functional and anatomical patency of urinary tract;
marked decrease of concretion relapses - 1-year-observation
Poster Reference Number 34.
The local immunity of
the urinary system in patients with recurrent Urolithiasis
Borisov AV. The local immunity of the urinary system in patients
with recurrent Urolithiasis. Lik Sprava. 1999 Apr-May;(3):111-5.
51 patients with urolithiasis complicated by pyelonephritis in the
active phase of inflammation were studied for the condition of local
immunity by determining the urine content of secretory
immunoglobulin A (SIgA) under conditions of combined treatment with
making use of phlogenzyme, a drug of II-generation systemic
enzymotherapy (SE). Recordable in this patients population was a
marked increase in the urine
level of SIgA. Incorporation in a combined treatment of phlogenzyme
results in normalizing the status of the urinary system local
immunity. Evidence has been obtained on the lack of parallelism in
the dynamics between the serum IgA content and urine concentration
of SIgA, which fact suggests independence of local immunity. Our
theory is that an appreciable increase in the urine level of SIgA in
patients with urolithiasis concurrent with pyelonephritis may have
an important part to play in the genesis of nephrolithiasis.
PMID:
10474953 [PubMed
- indexed for MEDLINE]